has role has attribute value has attribute antineoplastic agent antiprotozoal drug protease inhibitor organic molecular entity bortezomib C19H25BN4O4 CAS:179324-69-7 CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O CHEBI:52717 DrugBank:DB00188 Drug_Central:391 L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. LINCS:LSM-6281 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide PMID:18484921 PMID:18980173 PMID:21504411 PMID:21865767 PS 341 PS-341 Reaxys:8723817 Velcade Wikipedia:Bortezomib [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid bortezomib proteasome inhibitor drug liver toxicity Most-DILI-Concern